

Curriculum Vitae
Catherine E. Moore, MD

Practice Address:
Oncologist
July, 2014-Present
Oncology Specialists of Charlotte
2711 Randolph Road, Suite 100
Charlotte, NC 28207
cmoore@oncologycharlotte.com

Site Affiliations:
DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

Education:
2000-2004 Bachelor of Science with Distinction
Purdue University
West Lafayette, Indiana
2004-2008 Doctor of Medicine
Southern Illinois University School of Medicine
Springfield, Illinois
2008-2011 Internal Medicine Internship/Residency
Rush University Medical Center
Chicago, Illinois
2011-2014 Hematology/Oncology Fellowship
2013-2014 Chief Fellow
University of Iowa Hospitals & Clinics
Iowa City, Iowa

Certifications:
2012 American Board of Internal Medicine
2014 American Board of Oncology

Honors & Awards:
2000 Alpha Lambda Delta National Honor Society
2000 Golden Key National Honor Society
2004 Graduated with Distinction, Purdue University
2010 Teaching Resident
2013 Hematology-Oncology Chief Fellow

Professional Organizations:
2006-2008 Internal Medicine Interest Group President
2007-2008 American Medical Women's Associated – Cofounder
2009-2011 Rush Housestaff Association – Internal Medicine Representative
2011-Present American Society of Hematology
2011-Present American Society of Clinical Oncology
2012-Present American College of Physicians

Curriculum Vitae
Catherine E. Moore, MD

Teaching:

- Oncology Clinical Enrichment Class - December 2013
- Oncology Clinical Enrichment Class - September 2013
- Case Studies in Lung Cancer – September 2013
- Oncology Clinical Enrichment Class – June 2013
- HOBMT Fellows Conference: Chronic Myelogenous Leukemia – April 2013
- Cancer Center Committee Meeting. Quality Oncology Practice Initiative – Fall 2012
- HOBMT Morbidity and Mortality Conference – October 2012
- HOBMT Research Conference – March 2012
- HOBMT Fellows Conference: Uterine Leiomyosarcoma – November 2011

Formal Studies:

- ACGME Leadership Skills Training Program for Chief Resident – May 2013

Publications:

Weitfeldt D, Johnson A, **Veeder C**, Boehler ML, Schwind CJ, Rakinic J, Hassan I.

“The End of the Electronic Divide: Health Related Information Gathering Practices in Two Specialty Clinics.” American Journal of Surgery, 199(3), pp.364-368 (2010-03-18), March 2010.

Veeder C, Maciejewski J, Nathan S, Rich E, Davies S, Havey C, Fung H.

“Younger Age and CMV Negativity are Positive Prognostic Factors in Match Unrelated Donor Stem Cell Transplant.” ASCO online, 2007

Veeder C, Davies S, Havey C, Maciejewski J, Nathan S, Gregory S, Venugopal P, Shammo J, Fung H.

“The Transplant Outcomes of a 10/10 Matched Unrelated Donor Stem Cell Transplant is Similar to a HLA Identical Related Donor Transplant.” Blood (ASH Annual Meeting Abstracts), November 2009; 114:4346

Moore C, Darbro B, Berg D, Clamon C, Askeland R, Abu Hejleh T.

“ALK, MET and HER2 in Esophageal Adenocarcinoma with Signet Ring Cell Morphology.”
Gastrointestinal Cancer Symposium 2014. San Francisco, CA.

Clinical Research:

Sub-Investigator – Novartis Protocol CLEE011A2404: An Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor–Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer With No Prior Hormonal Therapy for Advanced Disease (NCT02941926). 2017

Sub-Investigator – Pfizer Madeline Protocol A5481074: Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes in Advanced Breast Cancer. 2017


Sub-Investigator- Merrimack SHERBOC/ MM121-02-02-10 Protocol: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy. 2017

Curriculum Vitae
Catherine E. Moore, MD

Sub-Investigator – Pfizer Javelin Protocol B9991016: A Randomized, Double-Blind, Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck. 2018

Sub-Investigator – Ipsen protocol A-US-52030-358: Lanreotide and Octreotide LAR for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis. 2018

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.



Signature

3/19/2018

Date

